Latest 10-K annual reports
NASDAQ
FTCI
Ftc Solar, INCFTC Solar, Inc. reported a significant net loss of $79.6 million in 2025, despite a 110.5% revenue increase, and disclosed substantial doubt about its ability to continue as a going concern.
OID
Charging Robotics Inc. reports significant losses for fiscal year 2025, raising substantial doubt about its ability to continue as a going concern despite strategic acquisitions and initial product orders in the growing EV charging and micro-mobility markets.
NYSE
Permianville Royalty Trust reports mixed 2025 results with increased distributable income despite declining oil sales and reserves, driven by natural gas strength and cost controls.
NASDAQ
Infinite Eagle Acquisition Corp., a blank check company, filed its annual report detailing its successful $345 million IPO and private placement, and outlining its strategy to identify a business combination target.
NASDAQ
Cardinal Infrastructure Group Inc. reported significant revenue and Adjusted EBITDA growth for fiscal year 2025, driven by organic expansion and strategic acquisitions, while also detailing its recent IPO and future growth plans.
NYSE
Lument Finance Trust reported a net loss of $7.5 million for 2025, a significant decline from the prior year's profit, alongside reduced dividends and increased credit loss provisions.
NYSE
Planet Labs PBC reported a 26% increase in revenue to $307.7 million for fiscal year 2026, driven by defense and intelligence contracts, despite recording a net loss of $246.9 million.
NASDAQ
Bold Eagle Acquisition Corp., a SPAC, reported a net income of $9.76 million for 2025, driven by trust account interest, but faces substantial doubt about its ability to continue as a going concern with an October 2026 business combination deadline looming.
NYSE
Lowe's reports a 3.1% net sales increase to $86.3 billion in fiscal 2025, driven by strategic acquisitions and a focus on Pro customers, despite a decline in customer transactions.
NYSE
Aspen Aerogels, Inc. filed an amended annual report correcting an inventory balance error, while the underlying financials reveal a significant net loss and revenue decline for 2025.
AMEX
Battalion Oil Corporation reports a net income of $11.9 million for 2025, driven by derivative gains and cost reductions, amidst strategic asset divestitures and acquisitions, while addressing significant debt and NYSE listing compliance.
NYSE
Merrill Lynch Depositor, Inc. files its 2025 annual report for INDEXPLUS Trust Series 2003-1, emphasizing compliance and outlining risks associated with its structured product.
NASDAQ
Sutro Biopharma reported a net loss of $191.1 million for 2025, driven by strategic restructuring and a refocused pipeline on novel ADC candidates STRO-004, STRO-006, and STRO-227.
NASDAQ
Ares Capital Corporation files an amendment to its 2025 annual report to include the audited financial statements of its significant subsidiary, Ivy Hill Asset Management, L.P.
NYSE
PPLUS Trust Series GSC-2 filed its annual 10-K report for the fiscal year ended December 31, 2025, confirming compliance with servicing standards and detailing risks associated with its trust certificates.
NYSE
Veris Residential, L.P. filed an amended 2025 annual report to update corporate governance, executive compensation, and security ownership details.
NASDAQ
NRx Pharmaceuticals reports significant progress in its neuroplasticity drug pipeline and the expansion of its interventional psychiatry subsidiary, HOPE Therapeutics, despite facing substantial financial losses and a going concern warning.
NASDAQ
SRZN
Surrozen, Inc/deSurrozen, Inc. reported a significant increase in net losses for 2025, driven by non-cash charges and increased R&D, while advancing its Wnt-pathway ophthalmology pipeline and securing new financing.
NYSE
SBXE
Silverbox CORP VSilverBox Corp V, a blank check company, reported a net loss of $7.7 million for 2025 as it continues its search for an initial business combination, with $276 million held in trust.
NASDAQ
Aardvark Therapeutics has voluntarily halted enrollment and dosing in its pivotal Phase 3 HERO trial for ARD-101 and Phase 2 ARD-201 trials following reversible cardiac observations in a healthy volunteer study, leading to significant stock price decline.
NASDAQ
Greenland Technologies Holding Corporation reported an 8% revenue increase in 2025, driven by transmission product sales, despite the suspension of its HEVI electric industrial vehicle operations due to tariff uncertainty.
NASDAQ
SolarEdge Technologies, Inc. significantly improved its financial performance in 2025, reporting a 31.4% revenue increase and a return to gross profitability after a substantial loss in 2024, despite ongoing net losses and legal challenges.
NASDAQ
Context Therapeutics Inc. reported a net loss of $36.1 million for 2025 as it advanced its bispecific antibody pipeline for solid tumors, with key clinical trial data expected in 2026.
NASDAQ
Bionano Genomics reported a significant reduction in net losses for 2025, driven by cost-saving initiatives, but faces ongoing substantial doubt about its ability to continue as a going concern without further capital.
OQB
PRKR
Parkervision INCParkerVision, Inc. reported significant losses and negative cash flows for fiscal year 2025, raising substantial doubt about its ability to continue as a going concern, as it continues to rely heavily on patent enforcement litigation for future revenue.
NASDAQ
Yunhong Green CTI Ltd. reported a 10% increase in net sales to $19.7 million for fiscal year 2025, despite incurring a net loss of $2.53 million and facing going concern doubts.
NASDAQ
SMTC
Semtech CORPSemtech Corporation reported a 15% revenue increase to $1.05 billion in fiscal year 2026, driven by infrastructure and industrial markets, despite a net loss and significant goodwill impairment.
NASDAQ
TLPH
Talphera, INCTalphera, Inc. reported a net loss of $14.3 million for 2025, raising substantial doubt about its ability to continue as a going concern, despite focusing resources on its lead product candidate, Niyad.
NYSE
TGE Value Creative Solutions Corp, a blank check company, outlines its securities, governance, and search for a business combination in its latest annual report.
NASDAQ
ULBI
Ultralife CORPUltralife Corporation reported a net loss of $5.9 million for 2025, driven by a significant non-cash intangible asset impairment from a global rebranding initiative, despite robust revenue growth and record backlog in its Battery & Energy Products segment.